Want to see SE:MODTX full AI Analyst Report?

Modus Therapeutics Holding AB (MODTX) Price & Analysis

0 Followers

MODTX Stock Chart & Stats

kr0.30

-kr0.02(-1.23%)

At close: Mar 06 4:00 PM EST

kr0.30

-kr0.02(-1.23%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr3.13

Previous CloseN/A

Volume636.00

Average Volume (3M)841.43K

Market Cap

kr45.00M

Enterprise Valuekr39.62

Total Cash (Recent Filing)kr6.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.74

Next Earnings

Nov 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume409,277

30 Day Avg. Volume841,432

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetZero reported debt in 2023–2025 limits mandatory interest and principal obligations, giving the company more flexibility to direct capital toward its sickle-cell programs. This is a durable balance-sheet advantage, although it does not remove the need for future equity funding.

Focused Therapeutic StrategyA focused development strategy in sickle cell disease and related hematologic conditions can concentrate scarce resources on a defined unmet-need area. If programs progress, this specialization may support differentiated partnering or licensing discussions, though no material partnership is confirmed.

Multiple Potential Monetization RoutesThe stated model can create value through clinical milestones, licensing, partnerships, or eventual commercialization rather than requiring an immediate commercial launch. This gives the pipeline multiple potential funding and monetization routes, but they remain contingent and unconfirmed.

Bears Say

No Commercial RevenueThe absence of revenue through 2025 confirms that the company remains dependent on development progress rather than customer demand or product sales. This limits financial visibility and leaves future value reliant on clinical outcomes, funding access, or a strategic transaction.

Persistent And Worsening Cash BurnPersistent negative operating and free cash flow means the business cannot currently fund development internally. The deterioration in 2025 increases the likelihood of additional capital requirements, making runway and financing execution important structural risks.

Financing And Dilution RiskThe volatile equity base and continued losses indicate reliance on recapitalization to sustain operations. Future equity raises could dilute existing holders, while limited financial resources may constrain development priorities if external funding becomes less available.

MODTX FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was kr0.21 and its highest was kr3.13 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is kr45.00M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Nov 24, 2026 which is in 88 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Aug 26, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in SE:MODTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.